Literature DB >> 22810367

Serum vitronectin levels in patients with Behçet's disease.

Ali Yalçındağ1, Aslıhan Uzun, F Nilüfer Yalçındağ, Namık Delibaş.   

Abstract

BACKGROUND/AIMS: To determine serum vitronectin levels in Behçet patients with and without ocular involvement, and to evaluate the relationship between vitronectin concentrations and clinical manifestations of Behçet's disease (BD).
METHODS: Sixty-five patients with BD and 21 control subjects were included. All patients were queried for the clinical manifestations of BD. Serum vitronectin concentrations were determined by using in vitro enzyme immunoassay kits.
RESULTS: Serum vitronectin levels between the patients and the control subjects were not different. There was no statistically significant difference between vitronectin levels in Behçet patients with and without ocular involvement. No correlation was found between vitronectin concentrations and clinical manifestations.
CONCLUSION: This is the first study evaluating vitronectin levels in Behçet patients. Further studies involving larger numbers of subjects would be useful to improve our understanding of the functions of vitronectin in BD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22810367     DOI: 10.1007/s00011-012-0521-z

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  46 in total

1.  How to deal with Behcet's disease in daily practice.

Authors:  Fereydoun Davatchi; Farhad Shahram; Cheyda Chams-Davatchi; Hormoz Shams; Abdolhadi Nadji; Massoomeh Akhlaghi; Tahereh Faezi; Bahar Sadeghi Abdollahi
Journal:  Int J Rheum Dis       Date:  2010-05       Impact factor: 2.454

2.  Activated protein C levels in Behçet's disease and risk of venous thrombosis.

Authors:  Silvia Navarro; José María Ricart; Pilar Medina; Amparo Vayá; Piedad Villa; José Todolí; Amparo Estellés; María Luisa Micó; Justo Aznar; Francisco España
Journal:  Br J Haematol       Date:  2004-08       Impact factor: 6.998

3.  Evaluation of fibronectin, vitronectin, and leptin levels in coronary artery disease: impacts on thrombosis and thrombolysis.

Authors:  Hakan Ekmekci; Ozlem B Ekmekci; Huseyin Sonmez; Zeynep Ozturk; Nergiz Domanic; Emine Kokoglu
Journal:  Clin Appl Thromb Hemost       Date:  2005-01       Impact factor: 2.389

4.  How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation.

Authors:  H Mohri; T Ohkubo
Journal:  Am J Clin Pathol       Date:  1991-11       Impact factor: 2.493

Review 5.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

6.  Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice.

Authors:  S Konstantinides; K Schäfer; T Thinnes; D J Loskutoff
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

7.  Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin.

Authors:  Gerard Espinosa; Josep Font; Dolors Tàssies; Antonio Vidaller; Ramon Deulofeu; Alfons López-Soto; Ricard Cervera; Antoni Ordinas; Miguel Ingelmo; Joan-Carles Reverter
Journal:  Am J Med       Date:  2002-01       Impact factor: 4.965

8.  Protein C and protein S activities in Behçet's disease as risk factors of thrombosis.

Authors:  N Lenk; G Ozet; N Alli; O Coban; S Erbaşi
Journal:  Int J Dermatol       Date:  1998-02       Impact factor: 2.736

9.  Ocular manifestations of late-onset behçet disease.

Authors:  Mehmet Citirik; Nilufer Berker; Murat Serkan Songur; Seyhan Sonar Ozkan; Orhan Zilelioglu
Journal:  Ophthalmologica       Date:  2010-08-07       Impact factor: 3.250

10.  Endothelial cell activation and hypercoagulability in ocular Behçet's disease.

Authors:  Kiki Probst; Rob Fijnheer; Aniki Rothova
Journal:  Am J Ophthalmol       Date:  2004-05       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.